Martijn P Lolkema

Martijn P Lolkema

UNVERIFIED PROFILE

Are you Martijn P Lolkema?   Register this Author

Register author
Martijn P Lolkema

Martijn P Lolkema

Publications by authors named "Martijn P Lolkema"

Are you Martijn P Lolkema?   Register this Author

55Publications

1674Reads

18Profile Views

[Genetic testing in patients with cancer; new developments].

Ned Tijdschr Geneeskd 2019 May 20;163. Epub 2019 May 20.

Radboudumc, afd. Genetica, Nijmegen.

View Article

Download full-text PDF

Source
May 2019

Self-reported quality of life and hope in phase-I trial participants: An observational prospective cohort study.

Eur J Cancer Care (Engl) 2018 Nov 4;27(6):e12908. Epub 2018 Sep 4.

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ecc.12908DOI Listing
November 2018

Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?

Eur Urol 2018 09 19;74(3):292-293. Epub 2018 Mar 19.

Department of Medical Oncology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.002DOI Listing
September 2018

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation.

Psychooncology 2018 01 26;27(1):163-170. Epub 2017 Jul 26.

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pon.4487
Publisher Site
http://dx.doi.org/10.1002/pon.4487DOI Listing
January 2018

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Eur Urol 2017 09 20;72(3):411-423. Epub 2017 Jun 20.

Department of Medical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.06.012DOI Listing
September 2017

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Clin Cancer Res 2016 Dec 28;22(23):5738-5746. Epub 2016 Jul 28.

Department of Medical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1255DOI Listing
December 2016

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Bioanalysis 2016 10;8(2):123-34. Epub 2015 Dec 10.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/bio.15.235
Publisher Site
http://dx.doi.org/10.4155/bio.15.235DOI Listing
September 2016

Reply to L. Battistuzzi et Al.

J Clin Oncol 2013 Nov 7;31(32):4165-6. Epub 2013 Oct 7.

University Medical Center Utrecht, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.2755DOI Listing
November 2013

Stromal biology and therapy in pancreatic cancer.

Gut 2011 Jun 21;60(6):861-8. Epub 2010 Oct 21.

Li Ka Shing Centre, Cambridge Research Institute, Cancer Research UK, Cambridge, UK.

View Article

Download full-text PDF

Source
http://gut.bmj.com/cgi/doi/10.1136/gut.2010.226092
Publisher Site
http://dx.doi.org/10.1136/gut.2010.226092DOI Listing
June 2011

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.

Angiogenesis 2011 May 29;14(2):135-41. Epub 2010 Dec 29.

Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-010-9197-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102838PMC
May 2011

Genetic analysis of von Hippel-Lindau disease.

Hum Mutat 2010 May;31(5):521-37

Department of Medical Oncology, University Medical Center Utrecht, Universiteitsweg 100, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/66/4/2000.full.pdf
Web Search
http://doi.wiley.com/10.1002/humu.21219
Publisher Site
http://dx.doi.org/10.1002/humu.21219DOI Listing
May 2010

Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2.

Exp Cell Res 2008 Apr 5;314(6):1229-36. Epub 2008 Jan 5.

Laboratory of Experimental Oncology, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2007.12.020DOI Listing
April 2008

Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.

Eur J Hum Genet 2008 Jan 3;16(1):73-8. Epub 2007 Oct 3.

Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.ejhg.5201930DOI Listing
January 2008

The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.

FEBS Lett 2007 Oct 31;581(24):4571-6. Epub 2007 Aug 31.

Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, rm F02.126, 3584 CX Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2007.08.050DOI Listing
October 2007

Platelets take up the monoclonal antibody bevacizumab.

Clin Cancer Res 2007 Sep 12;13(18 Pt 1):5341-7. Epub 2007 Sep 12.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0847DOI Listing
September 2007

Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.

J Biol Chem 2005 Jun 11;280(23):22205-11. Epub 2005 Apr 11.

Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M503220200DOI Listing
June 2005

The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery.

Exp Cell Res 2004 Dec;301(2):139-46

Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2004.07.016DOI Listing
December 2004

Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.

FEBS Lett 2004 Jan;556(1-3):137-42

Department of Medical Oncology, University Medical Center Utrecht, P.O. Box 85500, 3500 GA, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0014-5793(03)01392-9DOI Listing
January 2004